Table 4 Serum metabolites were different between AS patients and controls, (log2FC > 2, p < 0.05) and their significance levels retested after adjusting for covariates (sex, age, race, BMI, hypertension, diabetes, and batch effects) using a multiple linear regression model (*metabolites that remained significant after covariate adjustments and had an AUC ≥ 0.7).

From: Serum metabolic profiling in rheumatic heart disease and degenerative aortic stenosis

Metabolite putative annotation

CVQC

FC

Log2FC

p value

FDR adj. p

Covariates adj. p

AUC

PA(8:0/13:0)

17

9.820

3.296

0.006851

0.093446

0.10871

0.67

But-2-enoic acid

19

2.253

1.172

0.010041

0.093446

0.17942

0.78

Undecylenic acid

30

3.406

1.768

0.014883

0.093446

0.5137

0.74

Palmitoylcarnitine

16

4.273

2.095

0.019539

0.093446

0.009297

0.74*

Phenylacetylglutamine

20

22.246

4.476

0.021653

0.093446

0.4854

0.65

Isocaproic acid

26

5.997

2.584

0.022827

0.093446

0.006952

0.78*

Taurine

19

0.218

-2.195

0.023621

0.093446

0.005571

0.68*

Butyrylcarnitine

30

2.164

1.114

0.030461

0.093446

0.14113

0.77

Ornithine

16

3.071

1.619

0.037634

0.093446

0.008324

0.81*

Sorbyl acetate

26

2.436

1.284

0.041651

0.093446

0.87969

0.72

Desmeninol

26

7.798

2.963

0.045933

0.093446

0.70091

0.72

Lauroylcarnitine

26

5.35

2.42

0.051666

0.093446

0.14405

0.73

  1. PA phosphatidic acid.
  2. p value adjustment for multiple testing performed with the Benjamin-Hochberg false discovery rate (FDR) adjustment method.
Back to article page